Medical/Pharmaceuticals

With Millions of Children's Lives on the Line, Bill Gates Says Humanity Is at a Crossroads

At 2025 Goalkeepers event, Gates lays out roadmap for saving millions more children's lives by 2045 if governments stretch every dollar and scale a pipeline of affordable, lifesaving innovations Announces new pledge to the Global Fund 2026-2028 replenishment to prevent deaths from AIDS, TB, and ...

2025-09-23 08:00 1282

Sweden, the world's first travel destination on prescription

A new research-backed initiative sees physicians recommending trips to Sweden for the health benefits. STOCKHOLM, Sept. 23, 2025 /PRNewswire/ -- A sauna in Swedish Lapland for better sleep quality, or cold plunges in the archipelago for improved circulation? Two out of three respondents in a new...

2025-09-23 06:29 2406

IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training

MELBOURNE, Australia, Sept. 23, 2025 /PRNewswire/ -- IMRA Surgical, an Australian-based company at the forefront of disruptive technology for surgical training solutions announces a collaboration with Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") a global leader in radiopharmaceu...

2025-09-23 05:19 1651

Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets

* Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody * Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 /PRNewswire...

2025-09-22 21:00 1766

Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeuti...

2025-09-22 21:00 1885

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer

BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS  (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its ...

2025-09-22 20:00 1541

LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting

BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...

2025-09-22 20:00 2958

Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First Dedicated Cancer Centre for Women

NEW DELHI, Sept. 22, 2025 /PRNewswire/ -- Apollo Hospitals Enterprise Ltd (AHEL) recently announced the launch ofApollo Athenaa – Asia's First Dedicated Cancer Centre for Women, located in E2-E3, Defence Colony, New Delhi. The centre was inaugurated by the Hon'ble Chief Minister ofDelhi, Smt. Rek...

2025-09-22 15:43 2258

PHASE Scientific Launches World's Largest Urine-Based Cervical Cancer (HPV) Screening Clinical Study, Marking New Era of Non-Invasive Cervical Cancer Screening

GUANG'AN, China, Sept. 22, 2025 /PRNewswire/ -- PHASE Scientific International Limited ("PHASE Scientific") today announced the official launch of the world's largest clinical study for urine-based cervical cancer (HPV) screening, with the first site established in Guang'an,Sichuan Province, Chin...

2025-09-22 15:39 1930

Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer

HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF-β bifunctional antibody fusion protein, in combination with ivonescimab ...

2025-09-22 14:51 1375

First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs

NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 onSeptember 19, ...

2025-09-22 12:29 1897

Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy

-          The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combinationwith semaglutide group compared to 57.1% in the sem...

2025-09-22 08:10 1621

WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends

SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, d...

2025-09-22 08:00 1569

Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025

SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic m...

2025-09-19 20:00 2420

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg...

2025-09-19 19:59 2647

Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes

SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...

2025-09-19 18:01 2456

DarwinCell Showcases novel MSC-based drug ALT001 at the 150th American Neurological Association Annual Meeting

BALTIMORE, Sept. 19, 2025 /PRNewswire/ -- The 150th American Neurological Association Annual Meeting (ANA 2025) was successfully held inBaltimore, USA, fromSeptember 13 to 16, 2025. The conference brought together leading global experts, scholars, and industry leaders in the field of neuroscience...

2025-09-19 17:28 1895

Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes

Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries SINGAPORE, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0. Since its...

2025-09-19 16:58 1819

Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes

Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries CANBERRA, Australia, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0....

2025-09-19 16:51 1720

Lenovo GOAST 4.0 Decodes Trillions of Cells, Accelerating Genome Analysis to 24 Minutes

Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries MANILA, Philippines, Sept. 19, 2025 /PRNewswire/ -- Lenovo today shared updates on the 4th generation of its Genomics Optimization and Scalability Tool –GOAST v4.0....

2025-09-19 16:04 1823
1 ... 33343536373839 ... 645